Therapy News and Research

RSS

Spiolto Respimat shown to be superior first line therapy over LABA/ICS for COPD

Boehringer Ingelheim today announced new data from two trials presented at the European Respiratory Society (ERS) International Congress 2015

29 Sep 2015

Clinical trial initiated to determine feasibility, safety of focused ultrasound to treat depression

The first patient with depression has been treated with focused ultrasound. This procedure marks the beginning of a pilot clinical trial to determine the feasibility and safety of MR-guided focused ultrasound to non-invasively destroy a small volume of tissue deep in the brain - the anterior limb of the internal capsule - a well-established target for treating severe depression.

29 Sep 2015

Study: Bright light therapy reduces depression and agitation in dementia sufferers

Dementia is most often associated with memory loss, but seniors who suffer from the condition also experience depression and agitation. These symptoms are often treated with medication.

29 Sep 2015

Tailorx trial data supports use of Oncotype DX test in patients with early stage breast cancer

Initial results were announced today from the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, a multi-center prospectively conducted trial of more than 10,000 women with early stage breast cancer sponsored by the National Cancer Institute, part of the National Institutes of Health, and led by the ECOG-ACRIN Cancer Research Group with support from Genomic Health, Inc.

29 Sep 2015

Cancer treatment does not affect pregnancy outcome, shows new study

Women who are pregnant when diagnosed with cancer can start treatment for their disease immediately and do not need to terminate their pregnancy due to worries over the effects of therapy on the development of their child.

29 Sep 2015

Phase II IMvigor 210 data shows atezolizumab may prevent progression of metastatic urothelial bladder cancer

Data presented today at the 2015 European Cancer Congress (ECC) demonstrates that the investigational immunotherapy atezolizumab may prevent progression of metastatic urothelial bladder cancer (mUBC) in all age groups by 2.1 months.

29 Sep 2015

European survey sheds light on decision-making criteria of physicians treating advanced lung cancer patients

Boehringer Ingelheim announced today results of a new European survey investigating therapy goals, prescribing habits and decision-making criteria of physicians treating patients with advanced lung cancer with adenocarcinoma histology after first-line chemotherapy.

29 Sep 2015

Study: Increased acetylation of histones promotes fear extinction in mice

The targeted modulation of gene activity and cellular signaling pathways could provide a new approach to the treatment of fear and anxiety states according to the recent findings of a project sponsored by the Austrian Science Fund FWF.

29 Sep 2015

Research posters support utility of EKF’s PointMan DNA enrichment technology for rapid detection of lung cancer mutations

EKF, announces two research posters supporting application of PointMan™ DNA enrichment technology, for rapid and sensitive detection of lung cancer mutations.

From EKF Diagnostics 29 Sep 2015

Unique molecule can bind HIV-infected cells to killer T cells

A unique molecule developed at Duke Medicine, the University of North Carolina at Chapel Hill and MacroGenics, Inc., is able to bind HIV-infected cells to the immune system's killer T cells. It could become a key part of a shock-and-kill strategy being developed in the hope of one day clearing HIV infection.

29 Sep 2015

New drug works better than current treatments for advanced kidney cancer

A new drug has been found superior to current treatments in slowing the growth of advanced kidney cancer in patients who became resistant to the first-line therapies that had kept it in check, according to results from a clinical trial led by Dana-Farber Cancer Institute.

29 Sep 2015

New targeted therapy shows promise against small cell lung cancer

Small cell lung cancer (SCLC) is an aggressive disease that is difficult to treat and is frequently only diagnosed when it has spread to other parts of the body (metastasised). Five-year survival rates in SCLC, which accounts for about 14% of all lung cancers, are very low, at only six percent. But today US researchers will present two novel findings with important implications for treatment at the 2015 European Cancer Congress.

29 Sep 2015

Roche launches the cobas EGFR Mutation Test v2 for use with either plasma or tumour tissue samples

Roche has announced the commercial availability in countries that accept the CE mark1 of the cobas® EGFR Mutation Test v2, the first oncology assay from Roche that utilises either plasma or tumour tissue as a sample. The test identifies 42 mutations in the epidermal growth factor receptor (EGFR) gene, the most of any In-vitro Diagnostic (IVD) on the market, and can also be used as an aid in selecting eligible patients with non-small cell lung cancer (NSCLC) for therapy with an EGFR tyrosine kinase inhibitor (TKI).

From Roche Sequencing and Life Science 28 Sep 2015

Genetic test identifies breast cancer patients that can avoid chemotherapy and remain relapse-free following five years of hormone therapy

Genomic Health has announced the presentation of the first results1 from the Trial Assigning IndividuaLised Options for Treatment (Rx), or TAILORx, a large, prospectively conducted trial designed and conducted by the ECOG-ACRIN Cancer Research Group under the sponsorship of the U.S. National Cancer Institute (NCI).

28 Sep 2015

Philips showcases latest patient-driven sleep and respiratory solutions at the European Respiratory Society International Congress 2015

Philips Respironics, a business of Royal Philips, will showcase its latest portfolio of sleep-disordered breathing and respiratory solutions September 26-29 at the European Respiratory Society (ERS) International Congress 2015 in Amsterdam. At booth 1.H_01, Hall 1, clinicians can experience the latest Philips sleep-disordered breathing solutions and new options for COPD management that connect and support the patient, clinician and caregiver to improve patient care and help patients to live active lives.

From Philips Healthcare 28 Sep 2015

Teva presents new Reslizumab data at European Respiratory Society (ERS) International Congress 2015

Teva Pharmaceutical Industries Ltd., has presented results from a post hoc analysis of two pivotal Phase III clinical trials showing that treatment with reslizumab reduced clinical asthma exacerbations (CAEs) by 75 percent versus placebo in a subgroup of patients with late onset asthma (diagnosed at 40 years of age and older) with elevated blood eosinophils, who were inadequately controlled on inhaled corticosteroids (ICS).

28 Sep 2015

FDA accepts Braeburn's resubmission of Probuphine NDA for review

Braeburn Pharmaceuticals, an Apple Tree Partners company, today announced that the U.S. Food and Drug Administration has accepted Braeburn's resubmission of the Probuphine New Drug Application (NDA) for review and set February 27, 2016 as the target date for Agency action.

28 Sep 2015

Clinical trial data from Array BioPharma's binimetinib and encorafenib presented at ECC 2015

Clinical trial results from Array BioPharma's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.

28 Sep 2015

ENA highlights need for transgender patient care awareness

A new article about a transgender patient's "freak show" experience in a U.S. emergency department, published online in the Journal of Emergency Nursing, is prompting the country's largest professional organization of emergency nurses to encourage transgender patient care awareness.

28 Sep 2015

Kolltan announces presentation of data from KTN0158 preclinical study in mast cell tumors at ESMO 2015

Kolltan Pharmaceuticals, Inc. today announced the presentation of data from a preclinical study evaluating KTN0158 in dogs with spontaneous mast cell tumors. KTN0158 is a proprietary, humanized anti-KIT IgG1 monoclonal antibody drug candidate being developed as a potential therapy for cancer and mast cell-related diseases.

28 Sep 2015

Therapy News and Research

Spiolto Respimat shown to be superior first line therapy over LABA/ICS for COPD

Clinical trial initiated to determine feasibility, safety of focused ultrasound to treat depression

Study: Bright light therapy reduces depression and agitation in dementia sufferers

Tailorx trial data supports use of Oncotype DX test in patients with early stage breast cancer

Cancer treatment does not affect pregnancy outcome, shows new study

Phase II IMvigor 210 data shows atezolizumab may prevent progression of metastatic urothelial bladder cancer

European survey sheds light on decision-making criteria of physicians treating advanced lung cancer patients

Study: Increased acetylation of histones promotes fear extinction in mice

Research posters support utility of EKF’s PointMan DNA enrichment technology for rapid detection of lung cancer mutations

Unique molecule can bind HIV-infected cells to killer T cells

New drug works better than current treatments for advanced kidney cancer

New targeted therapy shows promise against small cell lung cancer

Roche launches the cobas EGFR Mutation Test v2 for use with either plasma or tumour tissue samples

Genetic test identifies breast cancer patients that can avoid chemotherapy and remain relapse-free following five years of hormone therapy

Philips showcases latest patient-driven sleep and respiratory solutions at the European Respiratory Society International Congress 2015

Teva presents new Reslizumab data at European Respiratory Society (ERS) International Congress 2015

FDA accepts Braeburn's resubmission of Probuphine NDA for review

Clinical trial data from Array BioPharma's binimetinib and encorafenib presented at ECC 2015

ENA highlights need for transgender patient care awareness

Kolltan announces presentation of data from KTN0158 preclinical study in mast cell tumors at ESMO 2015

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News